NRD
XERS icon

Nebula Research & Development’s Xeris Biopharma Holdings XERS Stock Holding History

Nebula Research & Development’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,751
Closed -$96.9K – 889
2025
Q2 		$96.9K Buy
+20,751
New +$95.1K 0.01% 922

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Nebula Research & Development's XERS Position: Q3 2025 in Review

Nebula Research & Development sold out of Xeris Biopharma Holdings (XERS) in Q3 2025, closing a stake of 20,751 shares — an estimated $96.9K sold.

Nebula Research & Development first reported a position in XERS in Q2 2025 and held it in 1 quarter. The position peaked at $96.9K in Q2 2025. 230 funds tracked by Wall St. Rank hold XERS as of Q3 2025.

  • Nebula Research & Development reported no remaining Xeris Biopharma Holdings position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 20,751 Xeris Biopharma Holdings shares in Q3 2025, an estimated $96.9K.
  • Nebula Research & Development first reported a position in Xeris Biopharma Holdings in Q2 2025 and held it in 1 quarter.
  • Nebula Research & Development's Xeris Biopharma Holdings position peaked at $96.9K in Q2 2025.
  • 230 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.